Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants

Condition:   HIV Infections Interventions:   Biological: GEO-D02 DNA;   Biological: MVA/HIV62B Vaccine;   Biological: B63521^11 gp120;   Biological: IHV01 Protein;   Biological: Protein Placebo Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   HIV Vaccine Trials Network (HVTN), Fred Hutch / University of Washington;   GeoVax Labs, Inc;   Duke University;   Institute of Human Virology, School of Medicine, University of Maryland Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials